Medisch Centrum Alkmaar
Welcome,         Profile    Billing    Logout  
 10 Trials 
8 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Daniels, Johannes MA
CLEVER, NCT06079970: Confocal Laser Endomicroscopy VERification

Recruiting
N/A
208
Europe, US, RoW
Neelde Based Confocal Laser Endomicroscopy, Conventional diagnostic bronchoscopy
Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC), Mauna Kea Technologies
Lung Cancer, Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung, Neoplasm of Lung
10/25
10/25
Hendriks, MP
CAIRO5, NCT02162563 / 2013-005435-24: Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases

Recruiting
3
564
Europe
FOLFOX/ FOLFIRI with bevacizumab, - bevacizumab, - irinotecan, - leucovorin, - 5-fluorouracil, - oxaliplatin, FOLFOXIRI with bevacizumab, FOLFOX/ FOLFIRI with panitumumab, - panitumumab
Dutch Colorectal Cancer Group
Colorectal Cancer, Liver Metastases
08/22
07/25
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
CrEATE, NCT06434896: Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC- Trial

Recruiting
N/A
1320
Europe
ctDNA analysis after surgery
UMC Utrecht, Personal Genome Diagnostics (PGDx), The Netherlands Cancer Institute
Circulating Tumor DNA, Recurrence, Colon Cancer Stage II
03/35
03/35
ORCHESTRA, NCT01792934: Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases

Recruiting
N/A
478
Europe
XELOX regimen according to standard procedures, FOLFOX regimen according to standard procedures, Surgery, radiofrequency ablation (RFA), transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE), stereotactic body radiation therapy (SBRT), Bevacizumab, tumor biopsy
Radboud University Medical Center, Erasmus Medical Center
Multi-organ Metastatic Colorectal Cancer
07/23
07/25
PLCRC, NCT02070146: Prospective Data Collection Initiative on Colorectal Cancer

Recruiting
N/A
50000
Europe
Dutch Colorectal Cancer Group
Colorectal Cancer
01/50
01/51
Willigendael, Edith
OASIS, NCT05911451: Optimizing Access Surgery In Senior Hemodialysis Patients

Recruiting
N/A
195
Europe
Arteriovenous fistula creation, Arteriovenous graft placement, Central venous catheter placement
Maastricht University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development
Vascular Access Complication, Hemodialysis Access Failure, Dialysis Access Malfunction, Arteriovenous Fistula, Arteriovenous Graft, Central Venous Catheter Related Bloodstream Infection
05/25
05/25
Hendriks, M P
DORA, NCT03574571: A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Recruiting
3
738
Europe, US, RoW
Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Radium-223
Memorial Sloan Kettering Cancer Center, Bayer
Prostate Cancer
06/26
06/26
Scheurs, H
No trials found
Welling, A
No trials found
Smorenburg, Carolina
No trials found

Download Options